Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K.

Genet Med. 2014 Aug;16(8):644-5. doi: 10.1038/gim.2014.55. No abstract available.

2.

Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.

Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, Raymond D, Mirelman A, Saunders-Pullman R, Clark L, Ozelius L, Orr-Urtreger A, Giladi N, Bressman S; LRRK2 Ashkenazi Jewish Consortium.

Neurology. 2015 Jul 7;85(1):89-95. doi: 10.1212/WNL.0000000000001708. Epub 2015 Jun 10.

3.

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium.

Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2. Epub 2011 Aug 30. Erratum in: Lancet Neurol. 2011 Oct;10(10):870.

4.

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Alcalay RN, Mejia-Santana H, Mirelman A, Saunders-Pullman R, Raymond D, Palmese C, Caccappolo E, Ozelius L, Orr-Urtreger A, Clark L, Giladi N, Bressman S, Marder K; LRRK2 Ashkenazi Jewish Consortium.

Parkinsonism Relat Disord. 2015 Feb;21(2):106-10. doi: 10.1016/j.parkreldis.2014.09.033. Epub 2014 Nov 20.

5.

Lrrk2 in the limelight!

Farrer MJ.

Neurology. 2007 Oct 30;69(18):1732-3. No abstract available.

PMID:
17967990
6.

The importance of LRRK2 mutations in Parkinson disease.

Schapira AH.

Arch Neurol. 2006 Sep;63(9):1225-8. Review. No abstract available.

PMID:
16966498
7.

Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.

Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Dürr A, Tazir M, Wszolek ZK, Uitti RJ, Nichols WC, Griffith A, Hattori N, Leppert D, Watts R, Zabetian CP, Foroud TM, Farrer MJ, Brice A, Middleton L, Hentati F.

Arch Neurol. 2006 Sep;63(9):1250-4.

PMID:
16966502
8.

LRRK2 mutations and Parkinsonism.

Albrecht M.

Lancet. 2005 Apr 2-8;365(9466):1230. No abstract available.

PMID:
15811455
9.

Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.

Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10322-7. doi: 10.1073/pnas.1203223109. Epub 2012 Jun 11.

10.

Re: LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.

Bonifati V, Wu-Chou YH, Schweiger D, Fonzo AD, Lu CS, Oostra B.

Neurology. 2008 Jun 10;70(24):2348; author reply 2348-9. doi: 10.1212/01.wnl.0000317005.06662.01. No abstract available.

PMID:
18541891
11.

Low disease risk in relatives of north african lrrk2 Parkinson disease patients.

Troiano AR, Elbaz A, Lohmann E, Belarbi S, Vidailhet M, Bonnet AM, Lesage S, Pollak P, Cazeneuve C, Borg M, Feingold J, Dürr A, Tazir M, Brice A; French Parkinson Disease Genetic Study Group.

Neurology. 2010 Sep 21;75(12):1118-9. doi: 10.1212/WNL.0b013e3181f39a2e. No abstract available.

PMID:
20855856
12.

[LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease].

Lesage S, Leutenegger AL, Brice A.

Med Sci (Paris). 2005 Dec;21(12):1015-7. French. No abstract available.

13.

A trojan horse for Parkinson's disease.

Hu Y, Tong Y.

Sci Signal. 2010 Apr 6;3(116):pe13. doi: 10.1126/scisignal.3116pe13. Review.

PMID:
20371768
14.

LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.

Elbaz A.

Lancet Neurol. 2008 Jul;7(7):562-4. doi: 10.1016/S1474-4422(08)70118-2. Epub 2008 Jun 6. No abstract available.

PMID:
18539536
15.

Leucine-rich repeat kinase 2 for beginners: six key questions.

Kett LR, Dauer WT.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009407. doi: 10.1101/cshperspect.a009407. Review.

16.

LRRK2 gene and tremor-dominant parkinsonism.

Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK.

Arch Neurol. 2006 Sep;63(9):1346-7. No abstract available.

PMID:
16966525
17.

LRRK2 mutations and Parkinsonism.

Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ.

Lancet. 2005 Apr 2-8;365(9466):1229-30. No abstract available.

PMID:
15811454
18.

New LRRK2 variants identified in Parkinson's disease.

Tan EK, Schapira AH.

Eur J Neurol. 2011 Mar;18(3):369-70. doi: 10.1111/j.1468-1331.2010.03163.x. No abstract available.

PMID:
20629720
19.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

20.

LRRK2 mutations in Basque patients with Parkinson's disease.

Zarranz JJ, Gómez-Esteban JC.

Lancet Neurol. 2008 Oct;7(10):866-7; author reply 867. doi: 10.1016/S1474-4422(08)70204-7. No abstract available.

PMID:
18848304

Supplemental Content

Support Center